abrdn plc Grows Stock Position in The Clorox Company (NYSE:CLX)

abrdn plc grew its position in shares of The Clorox Company (NYSE:CLX) by 3.1% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 560,714 shares of the company’s stock after purchasing an additional 16,811 shares during the period. abrdn plc owned approximately 0.45% of Clorox worth $90,956,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the company. Innealta Capital LLC purchased a new stake in Clorox during the 2nd quarter worth $30,000. Trifecta Capital Advisors LLC increased its position in shares of Clorox by 139.8% during the second quarter. Trifecta Capital Advisors LLC now owns 223 shares of the company’s stock worth $30,000 after acquiring an additional 130 shares during the last quarter. First Foundation Advisors acquired a new position in shares of Clorox in the first quarter worth about $31,000. Family Firm Inc. purchased a new position in Clorox in the second quarter valued at about $31,000. Finally, Quarry LP grew its stake in Clorox by 99.1% during the 2nd quarter. Quarry LP now owns 229 shares of the company’s stock valued at $31,000 after purchasing an additional 114 shares in the last quarter. 78.53% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Clorox

In other Clorox news, EVP Angela C. Hilt sold 1,733 shares of the business’s stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $165.52, for a total transaction of $286,846.16. Following the sale, the executive vice president now directly owns 13,471 shares in the company, valued at approximately $2,229,719.92. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.51% of the stock is currently owned by insiders.

Clorox Trading Down 0.6 %

Clorox stock opened at $156.82 on Wednesday. The firm has a 50-day moving average price of $161.02 and a two-hundred day moving average price of $145.82. The Clorox Company has a 52-week low of $114.68 and a 52-week high of $169.09. The firm has a market capitalization of $19.48 billion, a price-to-earnings ratio of 81.25, a PEG ratio of 3.19 and a beta of 0.41. The company has a quick ratio of 0.63, a current ratio of 1.03 and a debt-to-equity ratio of 5.04.

Clorox (NYSE:CLX) last issued its quarterly earnings data on Thursday, August 1st. The company reported $1.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.54 by $0.28. The business had revenue of $1.90 billion during the quarter, compared to analyst estimates of $1.97 billion. Clorox had a return on equity of 281.12% and a net margin of 3.95%. Sell-side analysts expect that The Clorox Company will post 6.64 earnings per share for the current year.

Clorox Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, November 7th. Investors of record on Wednesday, October 23rd will be issued a $1.22 dividend. This represents a $4.88 annualized dividend and a yield of 3.11%. The ex-dividend date is Wednesday, October 23rd. Clorox’s payout ratio is currently 252.85%.

Analyst Ratings Changes

A number of analysts have recently weighed in on CLX shares. JPMorgan Chase & Co. raised their price target on shares of Clorox from $148.00 to $174.00 and gave the stock a “neutral” rating in a research report on Friday, October 11th. Wells Fargo & Company cut their target price on shares of Clorox from $135.00 to $130.00 and set an “underweight” rating on the stock in a research note on Wednesday, July 10th. Jefferies Financial Group upgraded Clorox from a “hold” rating to a “buy” rating and lifted their price target for the stock from $174.00 to $187.00 in a research note on Tuesday, October 1st. BNP Paribas upgraded Clorox to a “strong sell” rating in a research note on Friday, September 6th. Finally, Barclays lifted their target price on Clorox from $130.00 to $137.00 and gave the stock an “underweight” rating in a research report on Friday, October 11th. Six analysts have rated the stock with a sell rating, nine have assigned a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $150.14.

Clorox Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.